Further to this, we have also identified a new in vivo target of PBT2, PP2A, which is involved in the pathogenesis of neurodegenerative diseases (including AD and other tauopathies) and which is considered to be a major therapeutic target to limit the pathological accumulation of the tau protein. Here, MAPT is linked to tauopathy.